These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 573066)

  • 1. Hematology problem. Myeloproliferative disorders.
    Saumur JH; Coleman ML; Larson LM
    Am J Med Technol; 1979 Jul; 45(7):634-7. PubMed ID: 573066
    [No Abstract]   [Full Text] [Related]  

  • 2. [JAK2 mutation and thrombosis - recommendations for screening].
    Linnemann B; Lindhoff-Last E
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
    [No Abstract]   [Full Text] [Related]  

  • 3. [Myeloproliferative syndrome].
    Nowotny P; Preussfner S; Konrad H; Engelmann C; Günther I
    Z Gesamte Inn Med; 1976 Apr; 31(8):250-4. PubMed ID: 986731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Unusual case of chronic myeloproliferative syndrome].
    Tosato F; Fossaluzza V
    Arch Sci Med (Torino); 1982; 139(4):531-5. PubMed ID: 6891999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
    Kvasnicka HM; Thiele J
    Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic studies in Philadelphia chromosome-negative myeloproliferative disorders, particularly polycythaemia rubra vera.
    Lawler SD
    Clin Haematol; 1980 Feb; 9(1):159-74. PubMed ID: 6768481
    [No Abstract]   [Full Text] [Related]  

  • 9. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia.
    Borze I; Mustjoki S; Juvonen E; Knuutila S
    Haematologica; 2008 Jul; 93(7):1098-100. PubMed ID: 18591627
    [No Abstract]   [Full Text] [Related]  

  • 11. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of cytogenetic methods in the diagnosis and differential diagnosis of myeloproliferative diseases (review of the literature and personal data)].
    Fleĭshman EV; Volkova MA
    Probl Gematol Pereliv Krovi; 1970 Aug; 15(8):53-8. PubMed ID: 4935743
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the assays of endogenous colony formation and serum erythropoietin on the diagnosis of polycythemia vera and essential thrombocythemia.
    Mossuz P;
    Semin Thromb Hemost; 2006 Apr; 32(3):246-50. PubMed ID: 16673278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report on essential thrombocythemia.
    Cancer Genet Cytogenet; 1981 Oct; 4(2):138-42. PubMed ID: 7199375
    [No Abstract]   [Full Text] [Related]  

  • 16. 5q-syndrome presenting as essential thrombocythemia: myelodysplastic syndrome or chronic myeloproliferative disorders?
    Koike T; Uesugi Y; Toba K; Narita M; Fuse I; Takahashi M; Shibata A
    Leukemia; 1995 Mar; 9(3):517-8. PubMed ID: 7885050
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis and management of myeloproliferative disorders.
    Laszlo J; Huang AT
    Curr Probl Cancer; 1977 Jul; 2(1):1-42. PubMed ID: 268266
    [No Abstract]   [Full Text] [Related]  

  • 18. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical aspects of myeloproliferative disorders excluding CML].
    Komatsu N
    Rinsho Ketsueki; 2008 Oct; 49(10):1411-9. PubMed ID: 18833926
    [No Abstract]   [Full Text] [Related]  

  • 20. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
    Pikman Y; Levine RL
    Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.